Medisafe 1 Technologies Board of Directors Approves Development of New Products for Intravenous Infusion and Blood Banks

November 22, 2010

JERUSALEM, November 22, 2010 /PRNewswire-FirstCall/ — Medisafe 1
Technologies Corp. (OTCBB: MFTH), a developer of patented technologies that
physically prevent unauthorized administration of prescription medications,
announced today that that the company’s board of directors has approved the
research and development of two new medical locking device products.

In addition to the company’s patented syringe locking device, the company
will now seek to develop bar-coded locking devices for intravenous infusion
bags, as well as blood transfusion bags.

It is estimated that the new technology will be ready for demonstration
within three months’ time.

The locking devices will physically prevent the intravenous
administration of medications or blood, unless the prescribed dosages and/or
blood type of the intended patient are first confirmed electronically.

“Human errors, both the improper labeling of bags as well as improper
administration, are among the leading causes of blood transfusion related
deaths,” said, Jacob Elhadad, CEO of Medisafe 1 Technologies. “Applying the
concepts behind our patented syringe bar-coding and locking device technology
to transfusion and infusion bags can contribute to a reduction in the number
of preventable deaths in hospitals.

“In addition, this technology can significantly reduce legal malpractice
and hospital insurance fees,” Elhadad added.

About Medisafe 1 Technologies

Medisafe 1 Technologies seeks to effectively prevent unauthorized
administration of a drug or medicinal substance by hypodermic needle.
Medisafe’s patented technology is a medical assembly with a locking mechanism
that is intended to ensure the substance cannot be released from the
hypodermic needle without positive pre-matching between the substance and its
intended patient.

Forward-Looking Statements

This letter contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933 as amended and Section 21E of the
Securities Exchange Act of 1934 as amended. All forward-looking statements
are inherently uncertain, based on current expectations and assumptions
concerning future events or future performance of Medisafe 1 Technologies
Corp., and its technologies. In evaluating such statements, prospective
investors should review carefully various risks and uncertainties identified
in this release, as actual results may differ materially from those
indicated. Medisafe 1 Technologies Corp. public filings may be viewed at

    Jacob Elhadad

SOURCE Medisafe 1 Technologies Corp.

Source: newswire

comments powered by Disqus